Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Analysis: Trump’s personal interests in the crypto industry may jeopardize the passage of the FIT21 bill

Analysis: Trump’s personal interests in the crypto industry may jeopardize the passage of the FIT21 bill

金色财经金色财经2026/05/30 22:17
Show original
Jinse Finance reported that on May 31, Trump’s election as president in 2024 and his embrace of cryptocurrencies are widely considered a major victory for the digital asset industry. However, Trump’s personal interests in this field have sparked some turbulence. As Congress accelerates the advancement of the Clarity Act, legislation aimed at establishing rules for digital assets and potentially triggering a wave of institutional investment, Trump’s ever-expanding cryptocurrency empire is providing critics with new reasons to oppose the bill. Ahead of the fall midterm elections, this issue has become increasingly contentious. Currently, the Clarity Act is awaiting a full Senate vote. Lawmakers are still debating whether to include ethical clauses that would restrict elected officials from participating in digital asset investment, with Trump’s significant interests in cryptocurrencies becoming one of the flashpoints of this debate.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma